Zacks: Analysts Expect Atara Biotherapeutics Inc (ATRA) Will Post Earnings of -$1.28 Per Share

Equities analysts expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to announce ($1.28) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings. The lowest EPS estimate is ($1.21) and the highest is ($1.20). Atara Biotherapeutics posted earnings per share of ($1.15) during the same quarter last year, which suggests a negative year over year growth rate of 11.3%. The company is scheduled to issue its next earnings results on Tuesday, February 26th.

On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.58) per share for the current fiscal year, with EPS estimates ranging from ($4.59) to ($4.58). For the next year, analysts anticipate that the firm will post earnings of ($5.12) per share, with EPS estimates ranging from ($5.19) to ($5.05). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.13) by ($0.16).

Several brokerages have recently weighed in on ATRA. BidaskClub upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 24th. Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 price target on shares of Atara Biotherapeutics in a research report on Friday, August 3rd. Finally, Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 3rd. Two analysts have rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $47.80.

In related news, insider Joe Newell sold 1,500 shares of the business’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $39.45, for a total transaction of $59,175.00. Following the completion of the transaction, the insider now directly owns 33,358 shares in the company, valued at $1,315,973.10. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Christopher Haqq sold 775 shares of the business’s stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $37.54, for a total value of $29,093.50. Following the transaction, the executive vice president now owns 331,355 shares of the company’s stock, valued at $12,439,066.70. The disclosure for this sale can be found here. Over the last quarter, insiders sold 93,249 shares of company stock valued at $3,592,222. 10.60% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of ATRA. BlackRock Inc. grew its position in Atara Biotherapeutics by 18.3% during the second quarter. BlackRock Inc. now owns 3,364,604 shares of the biotechnology company’s stock worth $123,650,000 after buying an additional 520,163 shares in the last quarter. JPMorgan Chase & Co. grew its position in Atara Biotherapeutics by 35.6% during the third quarter. JPMorgan Chase & Co. now owns 1,202,912 shares of the biotechnology company’s stock worth $49,741,000 after buying an additional 315,921 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Atara Biotherapeutics by 74.8% during the third quarter. Assenagon Asset Management S.A. now owns 415,520 shares of the biotechnology company’s stock worth $17,182,000 after buying an additional 177,852 shares in the last quarter. Eagle Asset Management Inc. grew its position in Atara Biotherapeutics by 11.2% during the third quarter. Eagle Asset Management Inc. now owns 1,624,958 shares of the biotechnology company’s stock worth $67,192,000 after buying an additional 164,219 shares in the last quarter. Finally, Northern Trust Corp grew its position in Atara Biotherapeutics by 27.1% during the second quarter. Northern Trust Corp now owns 497,371 shares of the biotechnology company’s stock worth $18,278,000 after buying an additional 105,935 shares in the last quarter.

Shares of NASDAQ ATRA opened at $37.83 on Tuesday. The firm has a market capitalization of $1.67 billion, a PE ratio of -9.46 and a beta of 2.59. Atara Biotherapeutics has a fifty-two week low of $12.65 and a fifty-two week high of $54.45.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

See Also: Float

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply